Impact of ocular hypotensive lipids on clinically significant diabetic macular edema

Abstract

Purpose

To study the impact of ocular hypotensive lipids (OHL) on the incidence, progression, and response to treatment of clinically significant diabetic macular edema (CSDME).

Methods

A total of 379 patients (232 female, 147 male) with a history of diabetes mellitus (DM) and primary open-angle glaucoma (POAG) were identified and included in the study. Patients were stratified into groups based on CSDME development and OHL exposure. Main outcome measures included time to development of CSDME, total duration of OHL exposure, and duration of DM and POAG.

Results

Seven patients (1.8%) developed CSDME after OHL exposure (group 1A), 15 (4.0%) developed CSDME prior to OHL exposure (group 1B), and 197 (52.0%) were treated with OHL but never developed CSDME (group 2). Of patients not exposed to OHL, 22 (5.8%) developed CSDME (group 3) and 138 (36.4%) did not (group 4). Mean duration of DM was longer (p<0.0001) in patients who developed CSDME (20.2 years) compared to patients who did not (12.4 years). There was no difference (p=0.67) in the amount of OHL exposure between patients who developed CSDME (4.1 years) and patients who did not (4.6 years). Once developed, there was no difference in the interval until CSDME resolution between OHL treated (17.8 mo) and untreated (12.7 mo) patients (p=0.36).

Conclusions

The CSDME development correlated most strongly with the duration of diabetes, irrespective of OHL use. Ocular hypotensive lipids treatment of POAG seems not to affect the incidence, progression, or response to treatment of CSDME in diabetes.

Keywords

Clinically significant diabetic macular edema Diabetes mellitus Ocular hypotensive lipids Primary open-angle glaucoma

Get full access to this article

View all access options for this article.

References

Lightman

, Towler

H.M.

. Diabetic retinopathy. Clin Cornerstone 2003; 5: 12–21.

Cruz

, Gregor

Z.J.

. The Retina, 4th ed. St. Louis: Mosby Elsevier Health Science; 2006: 2632–44.

Pradhan

, Fong

, March

Angiotensin-converting enzyme inhibition for the treatment of moderate to severe diabetic retinopathy in normotensive Type 2 diabetic patients. A pilot study.

J Diabetes Complications 2002; 16: 377–81.

Cha

Y.J.

, Kim

S.J.

. The therapeutic effects of angiotensin-converting enzyme inhibitors in severe non-proliferative diabetic retinopathy. Korean J Ophthalmol 2007; 21: 28–32.

Colucciello

. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol 2005; 123: 1273–5.

Fong

D.S.

, Contreras

. Glitazone use associated with diabetic macular edema. Am J Ophthalmol 2009; 147: 583–6.

Ambrosius

W.T.

, Danis

R.P.

, Goff

D.C.

Jr ; ACCORD Study Group. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol 2010; 128: 312–8.

Warwar

R.E.

, Bullock

J.D.

, Ballal

. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998; 105: 263–8.

Miyake

, Miyake

, Maekubo

, Asakura

, Manabe

. Incidence of cystoid macular edema after retinal detachment surgery and the use of topical indomethacin. Am J Ophthalmol 1983; 95: 451–6.

10.

Moroi

S.E.

, Gottfredsdottir

M.S.

, Schteingart

M.T.

Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension.

Ophthalmology 1999; 106: 1024–9.

11.

Miyake

, Ibaraki

. Prostaglandins and cystoid macular edema. Surv Ophthalmol 2002; 47(Suppl 1): S203–18.

12.

American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Patterns Guidelines. Primary Open-Angle Glaucoma. San Francisco, CA: American Academy of Ophthalmology; 2010. Available at www.aao.org/ppp.

13.

Rowe

J.A.

, Hattenhauer

M.G.

, Herman

D.C.

. Adverse side effects associated with latanoprost. Am J Ophthalmol 1997; 124: 683–5.

14.

Wand

. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol 1997; 115: 1206–8.

15.

Wistrand

P.J.

, Stjernschantz

, Olsson

. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997; 41(Suppl 2): S129–38.

16.

Rossetti

, Chaudhuri

, Dickersin

. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. The results of a meta-analysis. Ophthalmology 1998; 105: 397–405.

17.

Hoyng

P.F.J.

, Rulo

A.H.

, Greve

E.L.

, Astin

, Gjötterberg

. Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: a review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv Ophthalmol 1997; 41(Suppl 2): S83–8.

18.

Chang

J.H.

, McCluskey

, Missotten

, Ferrante

, Jalaludin

, Lightman

. Use of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema? Br J Ophthalmol 2008; 92: 916–21.